Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis
The Interleukin 1 Genetics Consortium. The Lancet Diabetes & Endocrinology 2015:3(4);243-53
This paper investigates potential cardiovascular and other effects of long-term pharmacological interleukin 1 (IL-1) inhibition.
The results suggest that long-term dual IL-1α/β inhibition could increase cardiovascular risk and, conversely, reduce the risk of development of rheumatoid arthritis. The cardiovascular risk might, in part, be mediated through an increase in proatherogenic lipid concentrations.